OREGON HEALTH & SCIENCE UNIVERSITY (OHSU)
DALFAMPRIDINE TO IMPROVE BALANCE IN MULTIPLE SCLEROSIS: A PILOT STUDY
The MS Center at Oregon Health & Science University (OHSU) is currently recruiting people for research on dalfampridine (Ampyra©) and imbalance in people with Multiple Sclerosis. To participate you must:
- Be 20-59 years old
- Have multiple sclerosis
- Have poor balance
- Be able to walk at least 100m with or without a cane or other assistive device
- Have no other current medical conditions known to affect balance and gait, e.g. lower-extremity joint replacement, peripheral neuropathy, vestibular disorder, alcoholism, stroke, seizures, or be pregnant.
- Not have impaired renal function
Participation in the study requires that subjects undergo clinical and physiological assessments at OHSU on four separate occasions over the course of 12 weeks. This is a double-blind, placebo-controlled trial. Half of the subjects will receive dalfampridine and half will receive placebo.
This is a research study and not treatment. Subjects will be paid $30 for each visit.
If you would like further information about this study please contact: Dr. Michelle Cameron or Josh Adams at 503-220-8262 x52016.
MULTIPLE SCLEROSIS SURVEY STUDY
The Oregon Center for Complementary and Alternative Medicine in Neurology at Oregon Health & Science University (OHSU) is looking for people with multiple sclerosis (MS) to participate in a survey study. The purpose of this study is to gather information about mindfulness, stress, anxiety, depression, coping strategies, and quality of life in MS. You may be eligible to participate in the study if you meet all of the following criteria:
- Have a diagnosis of MS
- Are between 18 and 90 years of age
- Able to read and write in English
This study requires one visit to the OHSU MS Center to complete a variety of questionnaires and a blood draw. This visit is provided at no cost to you and is expected to last 2 to 2 1/2 hours.
If you meet the eligibility requirements described above and are interested in participating in this study, please call Angela Senders, ND at 503-494-7798 or email senders@ohsu.edu.
Principal investigator: Angela Senders, ND
OHSU IRB # 7989
Approved Dec. 1, 2011
NATALIZUMAB FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
The MS Center at Oregon Health & Science University (OHSU) is looking for people with multiple sclerosis to participate in a research study to evaluate the effects of natalizumab (Tysabri) on Secondary Progressive Multiple Sclerosis (SPMS). The purpose of this study is to see if the study drug is effective in slowing the progression of disability in SPMS.
Participants may qualify if between 18-58 years of age, have SPMS, and able to walk independently or with assistance.
Study participants are randomly assigned to receive either natalizumab or the placebo. All participants will receive an intravenous (IV) infusion every 4 weeks.
For more information about the study contact Melissa Tee at 503-494-3549.
Principal Investigator: Dr. Vijayshree Yadav, MD
OHSU IRB # 7557
Approved: Feb. 1, 2012
THE PORTLAND VA MEDICAL CENTER
LIPOIC ACID FOR NEUROPROTECTION IN SECONDARY PROGRESSIVE MS
The Portland VA Medical Center is looking for people with MS to participate in a study using lipoic acid. The purpose of this study is to learn if the antioxidant lipoic acid can help in secondary progressive multiple sclerosis (SPMS).
To be eligible for participation you must be between 40-70 years of age, have SPMS, and be able to get MRI scans.
People who take part in the study cannot be pregnant or breastfeeding, have uncontrolled diabetes or take insulin, have any condition other than MS that gradually worsens walking (if still walking), or have taken IV or oral steroids in the past 60 days.
The principal investigator for this study is Rebecca Spain, MD.
For more information about the study contact Elizabeth Heriza at 503-220-8262 x54594 or Elizabeth.Heriza@va.gov.
PROVIDENCE MS CENTER
PACIFIC NORTHWEST MULTIPLE SCLEROSIS REGISTRY
The goals are to accurately estimate the prevalence and geographic distribution of MS patients, to create a database for ongoing epidemiological and health services research in MS, and to develop an interactive MS network to provide training and improve access to specialized MS care.
Principal Investigator: Stanley Cohan, MD, PhD.
For more information, visit www.pacificNWms.org or contact the program staff at 503-216-1022.
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABATACEPT IN ADULTS WITH RELAPSING-REMITTING MS
Sponsor: National Institute of Allergy and Infectious Diseases
Principal Investigator: Stanley Cohan, MD, PhD.
For more information, please contact Chad Parks, Clinical Research Coordinator, at
503-216-2736.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFICACY OF NATALIZUMAB ON REDUCING DISABILITY PROGRESSION IN SUBJECTS WITH SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Sponsor: Biogen Idec
Principal Investigator: Stanley Cohan, MD, PhD.
For more information, please contact Jessica Hearn, Clinical Research Coordinator, at
503-216-1017.